PRLD

Over the past six months, Prelude Therapeutics' stock price has been impacted by several events. These include financial results conference calls, FDA clearance for a Phase I trial, earnings reports, analyst target price increases and rating changes, the appointment of a new Chief Medical Officer, a $90.0 million underwritten offering, presentation of preclinical data, a significant insider transaction, identification of shareholder dilution risk, and initiation of coverage by D. Boral Capital. The stock price experienced a substantial increase and high volatility.